Latest News - Valeant

Thursday, November 03, 2016 | Acquisitions/Mergers, Bausch+Lomb, Valeant

Valeant Exploring Sale of Eye Surgery Equipment Business

New reports reveal that Valeant is exploring a sale of its eye surgery equipment business – part of its Bausch + Lomb franchise – in an effort to pay down debt. The Wall Street Journal, citing …

Read the full story

Tuesday, November 01, 2016 | Earnings & Financials, Valeant

Valeant Said to Be in Talks for Sale of Salix to Takeda

Valeant Pharmaceuticals International is in talks to sell its Salix gastrointestinal drugs business to Takeda Pharmaceutical Co., according to a person familiar with the matter. The unit could go for …

Read the full story

Monday, October 31, 2016 | Earnings & Financials, Valeant

Valeant Ex-CEO, Ex-CFO Are Focus of U.S. Criminal Probe

U.S. prosecutors are focusing on Valeant Pharmaceuticals International Inc.’s former CEO and CFO as they build a fraud case against the company that could yield charges within weeks, according t…

Read the full story

Friday, September 23, 2016 | Health Care, Valeant

Valeant Avoids Double-Digit Price Hikes With 9.9 Percent Increases

In response to intensifying criticism over drug prices, Allergan chief executive Brent Saunders promised not to raise prices by more than single-digit percentage points. So far, no other head of a lar…

Read the full story

Monday, August 22, 2016 | Management/Leadership, Valeant

Valeant Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer

Valeant Pharmaceuticals International announced that Paul S. Herendeen has been appointed Executive Vice President, Finance and will take over the role of Chief Financial Officer from Robert L. Rosiel…

Read the full story

Thursday, August 18, 2016 | Earnings & Financials, Valeant

Valeant Shares Rise as Once-Burned Analysts Regain Optimism

Stock analysts are starting to come back around to Valeant Pharmaceuticals International Inc. after being burned by the company over the past year. The shares rose 13 percent to $30 at 4 p.m. Wednesda…

Read the full story

Wednesday, August 10, 2016 | Earnings & Financials, Valeant

Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results

  Total Revenues of $2.4 billion, a decrease of 11% versus the second quarter of 2015 GAAP EPS  ($0.88) and Adjusted EPS (non-GAAP)  $1.40 Cash Flow from Operations of $448 …

Read the full story

Monday, August 08, 2016 | Management/Leadership, Valeant

Valeant Announces Changes To Executive Management Team; New B+L Leader

Valeant Pharmaceuticals announced a series of leadership and organizational changes, including naming Ari Kellen, MBBCh, current executive vice president and company group chairman, as the leader…

Read the full story

Friday, July 22, 2016 | Miscellaneous, Bausch+Lomb, Valeant

FDA Raises Manufacturing Concerns in Complete Response Letter for Valeant's Vesneo Eye Drop

The FDA issued a complete response letter to Valeant Pharmaceuticals in relation to its filing for Vesneo (latanoprostene bunod), an IOP-lowering single-agent eye drop for patients with open angle gla…

Read the full story

Wednesday, June 15, 2016 | Earnings & Financials, Bausch+Lomb, Valeant

Valeant's New CEO Says Key Assets Can Be Sold

After months of confusion, Valeant Pharmaceutical’s new chief, Joseph Papa, said Tuesday the troubled company is looking to sell assets to reduce its massive debt load -- including its crown jew…

Read the full story

Monday, June 13, 2016 | Acquisitions/Mergers, Valeant

Valeant Said to Consider Sale of Egyptian Drugmaker Amoun

Valeant Pharmaceuticals International Inc. is considering the sale of Egyptian drugmaker Amoun Pharmaceutical Co. as the beleaguered Canadian company seeks to accelerate its debt-reduction plans, acco…

Read the full story

Tuesday, May 31, 2016 | Management/Leadership, Valeant

Valeant's Former CEO Will Stay on as an $83,000-a-Month Consultant

Michael Pearson may have gotten sacked from Valeant Pharmaceuticals earlier this year, but he will still collect a paycheck. The former CEO, who led the company through the thick of its drug-price gou…

Read the full story

Friday, May 27, 2016 | Acquisitions/Mergers, Valeant

Valeant Said to Have Rejected a Takeover Bid This Spring

Valeant Pharmaceuticals International received a joint takeover offer from Japan’s Takeda Pharmaceutical and TPG Capital Management this spring that the Canadian drugmaker rejected, according to…

Read the full story

Tuesday, May 24, 2016 | Miscellaneous, Bausch+Lomb, Valeant

Valeant CEO Papa Calls B&L Division a 'Core Franchise'

Valeant Pharmaceuticals International Inc. would contemplate selling off some assets but sees Bausch & Lomb Inc.’s ophthalmic division as a “core franchise” it should hang on to,…

Read the full story

Tuesday, May 10, 2016 | Earnings & Financials, Valeant

Valeant Reiterates Quarterly Outlook, Sees Filing on Time

Valeant Pharmaceuticals International Inc. reiterated its revenue and earnings estimates for the first quarter, saying it expects to submit its regulatory filing by June 10, ahead of a July 31 deadlin…

Read the full story
Load More